临床药师参与慢性阻塞性肺疾病临床路径管理的效果评价  

Clinical Pharmacists' Evaluation of Clinical Pathway in Chronic Obstructive Pulmonary Disease

作　　者：廖世雄[1] 李楚云[1] 陈美玲[1] 刘燕好 LIAO Shi-xiong, LI Chu-yun, LIU Yan-hao

机构地区：[1]惠州市中心人民医院药学部,广东惠州516001 [2]惠州市妇幼保健计划生育服务中心药剂科,广东惠州516001

出　　处：《中国药物经济学》2018年第7期98-101,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨临床药师参与慢性阻塞性肺疾病临床路径管理的作用和效果。方法选取2016年1月至2017年12月惠州市中心人民医院呼吸科收治的156例入院第一诊断为慢性阻塞性肺疾病患者作为研究对象,将2016年1-12月收治的74患者设为对照组,2017年1-12月的82例患者作为观察组。两组患者均接受既定的临床路径管理,给予统一既定的规范检查和相关药物治疗,同时观察组患者接受专科临床药师提供的临床路径药学管理服务。观察两组患者的临床疗效、住院时间、住院费用、药品费用、不良反应发生率和相关药品使用情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组患者的药品费用、总住院费用及药品不良反应发生率均显著低于对照组,差异均有统计学意义(均P<0.05);观察组患者抗菌药物、平喘药、祛痰和辅助用药的费用均显著低于对照组,差异均有统计学意义(均P<0.05)。结论对慢性阻塞性肺疾病患者实施临床药师参与的临床路径管理,在一定程度上规范了医师的用药合理性,确保患者临床用药安全、有效、经济。Objective To evaluate the role and effect of clinical pharmacists participating in clinical pathway management of chronic obstructive pulmonary disease.Methods 156 patients admitted to the Department of respiration of Huizhou Central People＇s Hospital from January 2016 to December 2017 were selected as the subjects for the first diagnosis of chronic obstructive pulmonary disease. 74 patients were treated in the 1-12 month of 2016 as the control group, and 82 patients in the 1-12 month of 2017 were used as the observation group. The two groups were treated with established clinical pathway management, unified established normative examination and related drug treatment, and the observation group received clinical pathway pharmacy management services provided by specialist clinical pharmacists. The clinical efficacy, length of stay, hospitalization expenses, drug cost, incidence of adverse reactions and the use of related drugs were observed in the two groups.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group （P〈0.05）. The drug cost,total hospitalization expenses and the incidence of ADR in the observation group were significantly lower than those in the control group （P〈0.05）, and the patients in the observation group were antiseptic, antiasthmatic and dispelling. The cost of phlegm and adjuvant drugs was significantly lower than that of the control group （P〈0.05）. Conclusion The clinical pathway management of clinical pharmacists in patients with chronic obstructive pulmonary disease, to a certain extent, standardizes the rationality of the physicians＇ medication, and ensures the safety, effectiveness and economy of the patients＇ clinical medication.

关 键 词：临床药师 临床路径 合理用药 

分 类 号：R563.9[医药卫生—呼吸系统]